Lantern Pharma Earnings Preview
Portfolio Pulse from Benzinga Insights
Lantern Pharma (NASDAQ:LTRN) is scheduled to release its quarterly earnings report on March 18, 2024, with analysts expecting an EPS of $-0.40. The company's past performance shows a history of beating EPS estimates, leading to significant share price movements. Shares have been trading at $7.35 as of March 14, reflecting a 67.33% increase over the last 52 weeks. Investors are advised to watch for the earnings report and particularly the company's guidance for future growth.
March 15, 2024 | 3:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Lantern Pharma is expected to report an EPS of $-0.40 for the upcoming quarter. Historical data shows significant stock price movements following earnings reports, especially when beating estimates.
Given Lantern Pharma's history of beating EPS estimates and the subsequent positive stock price reactions, there is a strong likelihood of a positive short-term impact on LTRN's stock price if the company beats the EPS estimate again. The 67.33% increase in share price over the last 52 weeks further supports investor optimism. However, the actual impact will heavily depend on the reported EPS and the future guidance provided by the company.
CONFIDENCE 80
IMPORTANCE 90
RELEVANCE 100